First human tests begin for new sepsis drug
NCT ID NCT06669403
Summary
This is an early safety study for a new drug called OPT101, designed for adults hospitalized with pneumonia that has led to sepsis. The main goal is to see if the drug is safe and how it moves through the body in this seriously ill group. Researchers will compare the drug to a placebo in a small group of 26 patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Denver Health and Hospital Authority
Denver, Colorado, 80204, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.